These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 9218194

  • 1. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E, Orth SR, Strzelczyk P.
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 4. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G.
    Isr J Med Sci; 1996 Dec 09; 32(12):1217-21. PubMed ID: 9007157
    [Abstract] [Full Text] [Related]

  • 5. [Are all antihypertensive drugs renoprotective?].
    Wolf S, Risler T.
    Herz; 2004 May 09; 29(3):248-54. PubMed ID: 15167950
    [Abstract] [Full Text] [Related]

  • 6. Nephroprotection by antihypertensive agents.
    Schmieder RE.
    J Cardiovasc Pharmacol; 1994 May 09; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [Abstract] [Full Text] [Related]

  • 7. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S.
    Am J Kidney Dis; 1990 Oct 09; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [Abstract] [Full Text] [Related]

  • 8. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A, Peeters P, Vanholder R.
    Acta Clin Belg; 2004 Oct 09; 59(1):44-56. PubMed ID: 15065696
    [Abstract] [Full Text] [Related]

  • 9. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR.
    Drugs; 2005 Oct 09; 65 Suppl 2():29-39. PubMed ID: 16398060
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G.
    Exp Nephrol; 1994 Oct 09; 2(4):220-8. PubMed ID: 8069658
    [Abstract] [Full Text] [Related]

  • 11. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME.
    J Hypertens Suppl; 1996 Dec 09; 14(6):S11-4. PubMed ID: 9023709
    [Abstract] [Full Text] [Related]

  • 12. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T, Honda T, Ohta S, Akashiba A, Takahashi T, Kameda T, Yoshii M, Minami J, Takahashi M, Ono H, Matsuoka H.
    Am J Hypertens; 2006 Dec 09; 19(12):1233-40. PubMed ID: 17161768
    [Abstract] [Full Text] [Related]

  • 13. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul 09; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 14. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I, Johnston CI.
    Kidney Int Suppl; 1997 Dec 09; 63():S19-22. PubMed ID: 9407414
    [Abstract] [Full Text] [Related]

  • 15. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F, Del Vecchio L, Andrulli S, Colzani S.
    Kidney Int Suppl; 2002 Dec 09; (82):S53-60. PubMed ID: 12410856
    [Abstract] [Full Text] [Related]

  • 16. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR.
    J Hum Hypertens; 2007 Oct 09; 21(10):770-9. PubMed ID: 17597800
    [Abstract] [Full Text] [Related]

  • 17. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C, Canadian Hypertension Education Program.
    Can J Cardiol; 2004 Jan 09; 20(1):41-54. PubMed ID: 14968142
    [Abstract] [Full Text] [Related]

  • 18. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.
    Taylor AA, Sunthornyothin S.
    Curr Hypertens Rep; 1999 Oct 09; 1(5):446-53. PubMed ID: 10981104
    [Abstract] [Full Text] [Related]

  • 19. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G, Cao Z, Cooper ME.
    Diabetes Technol Ther; 2002 Oct 09; 4(3):313-21. PubMed ID: 12165170
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hypertension in chronic kidney disease.
    Toto RD.
    Semin Nephrol; 2005 Nov 09; 25(6):435-9. PubMed ID: 16298269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.